Long-term results of the mucosal ablation of Barrett's esophagus: efficacy and recurrence

 

 Permissions and Reprints

Background and study aims: It has been postulated that the endoscopic ablation of Barrett’s esophagus can lead to complete eradication of the disease. This study was undertaken to evaluate the efficacy of endoscopic eradication therapy for Barrett’s esophagus and the rates of recurrence of intestinal metaplasia.

Patients and methods: As part of an initial randomized controlled trial, patients with nondysplastic or low grade dysplastic Barrett’s esophagus underwent mucosal ablation. Following ablation, the patients had annual surveillance endoscopies. Recurrence was defined as the presence of intestinal metaplasia after initial complete eradication had been achieved.

Results: A total of 28 patients with Barrett’s esophagus were followed for a mean of 6.4 years after ablation therapy. At baseline, the majority of the patients had nondysplastic Barrett’s esophagus (79 %). Initial complete eradication of intestinal metaplasia was achieved at a mean of 4.1 months. During long-term follow-up, initial recurrence of intestinal metaplasia was seen in 14 of the 28 of patients (50 %) at a mean of 40 months, and further maintenance ablation therapy was applied. At the final follow-up, 36 % of the patients had complete eradication of intestinal metaplasia, 18 % of the patients had intestinal metaplasia, and 21 % had died of unrelated causes; invasive esophageal adenocarcinoma had developed in 1 patient.

Conclusions: The long-term results of this study demonstrate a recurrence rate of 50 % after complete eradication of Barrett’s esophagus with endoscopic eradication therapy. In addition, re-recurrence (in 36 %), even after further maintenance endoscopic eradication therapy, and deaths unrelated to the disease (21 %) occurred. Complete remission of Barrett’s esophagus appears to be a difficult goal to achieve. These results call into question the role of ablation in patients with low risk Barrett’s esophagus.

• References

• 1 Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797
  CrossrefPubMedGoogle Scholar
• 2 Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146
  CrossrefPubMedGoogle Scholar
• 3 de Jonge PJF, van Blankenstein M, Looman CWN et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036
  CrossrefPubMedGoogle Scholar
• 4 Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-1057
  CrossrefPubMedGoogle Scholar
• 5 Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 1375-1383
  CrossrefPubMedGoogle Scholar
• 6 Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255
  CrossrefPubMedGoogle Scholar
• 7 Rastogi A, Puli S, El-Serag HB et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67: 394-398
  CrossrefPubMedGoogle Scholar
• 8 Wani S, Falk G, Hall M et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227 .e1
  CrossrefPubMedGoogle Scholar
• 9 Gaddam S, Singh M, Balasubramanian G et al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology 2013; 145: 548-553 .e1
  CrossrefPubMedGoogle Scholar
• 10 Wani S, Falk GW, Post J et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011; 141: 1179-1186 .e1
  CrossrefPubMedGoogle Scholar
• 11 Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-1530
  CrossrefPubMedGoogle Scholar
• 12 Phoa KN, van Vilsteren FG, Weusten BL et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217
  CrossrefPubMedGoogle Scholar
• 13 Sharma P, Wani S, Weston AP et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long-term results. Gut 2006; 55: 1233-1239
  CrossrefPubMedGoogle Scholar
• 14 Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009; 361: 2548-2556
  CrossrefPubMedGoogle Scholar
• 15 Allison H, Banchs MA, Bonis PA et al. Long-term remission of nondysplastic Barrett's esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow-up. Gastrointest Endosc 2011; 73: 651-658
  CrossrefPubMedGoogle Scholar
• 16 Mork H, Al-Taie O, Berlin F et al. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol 2007; 42: 23-27
  CrossrefPubMedGoogle Scholar
• 17 Sie C, Bright T, Schoeman M et al. Argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus: late outcomes from two randomized trials. Endoscopy 2013; 45: 859-865
  Article in Thieme ConnectPubMedGoogle Scholar
• 18 Pascarenco OD, Boeriu A, Mocan S et al. Barrett's esophagus and intestinal metaplasia of gastric cardia: prevalence, clinical, endoscopic and histological features. J Gastrointestin Liver Dis 2014; 23: 19-25
  PubMedGoogle Scholar
• 19 Saligram S, Chennat J, Hu H et al. Endotherapy for superficial adenocarcinoma of the esophagus: an American experience. Gastrointest Endosc 2013; 77: 872-876
  CrossrefPubMedGoogle Scholar
• 20 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 42: 781-789
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Haidry RJ, Dunn JM, Butt MA et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013; 145: 87-95
  CrossrefPubMedGoogle Scholar
• 22 Gupta M, Iyer PG, Lutzke L et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology 2013; 145: 79-86
  CrossrefPubMedGoogle Scholar